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Abstract:  
 
Fullerenes represent a group of compounds having unique properties that make them attractive 
candidates for use as a platform for developing new medical applications. The carbon cage 
(usually C60 and C70) of empty cage fullerenes (Figure 1-left/middle) are being developed as 
therapeutics for disease processes such as multiple sclerosis, neurodegeneration, HIV infection, 
cancer, radiation exposure, ischemia, allergic disease, infectious disease, and general 
inflammation. Metallo-fullerenes (Figure 1-right; that have metals enclosed within the carbon 
cage) are being developed into new biomarker homing, diagnostic contrast agents for MRI. 
Lastly, a new class of theranostics are being developed that combine cell targeting 
capabilities/imaging with a therapeutic payload. Their inherent properties combined with their 
ability to be derivatized with side chains results in almost limitless new chemical structures 
making them ideal platform molecules for new solutions to basic biological problems. However, 
one of the biggest obstacles that have kept this class of compounds from potentially improving 
human health and reducing health care costs is the concern about toxicity. This has been due, in 
part, to the lack of standard structural relationships that affect biological outcomes of Fullerene 
Derivatives (FD). 
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Fullerenes represent a group of compounds having unique 
properties that make them attractive candidates for use as a platform 
for developing new medical applications. The carbon cage (usually 
C60 and C70) of empty cage fullerenes (Figure 1-left/middle) are being 
developed as therapeutics for disease processes such as multiple 
sclerosis, neurodegeneration, HIV infection, cancer, radiation exposure, 
ischemia, allergic disease, infectious disease, and general inflammation. 
Metallo-fullerenes (Figure 1-right; that have metals enclosed within 
the carbon cage) are being developed into new biomarker homing, 
diagnostic contrast agents for MRI. Lastly, a new class of theranostics 
are being developed that combine cell targeting capabilities/imaging 
with a therapeutic payload. Their inherent properties combined with 
their ability to be derivatized with side chains results in almost limitless 
new chemical structures making them ideal platform molecules for 
new solutions to basic biological problems. However, one of the biggest 
obstacles that have kept this class of compounds from potentially 
improving human health and reducing health care costs is the concern 
about toxicity. This has been due, in part, to the lack of standard 
structural relationships that affect biological outcomes of Fullerene 
Derivatives (FD). 
Of course, toxicity considerations are implicit when contemplating 
human use for novel compounds such as fullerenes. To this end there 
have been a number of studies examining the toxicity using a myriad 
of fullerene preparations. However, the results of most of these studies 
are conflicting, inconclusive, and the subject of much debate. One of 
the most “damaging” fullerene studies (that was subsequently proven 
to be unfounded) exposed juvenile bass to un-derivatized C60, which 
is insoluble in water [1]. Unfortunately the authors did not include 
a control that provided insights into whether the observed effects 
were simply due to large aggregated particles/THF contaminants or 
whether they were specific to the chemical nature of C60. Yet there was 
widespread publicity that concluded  fullerenes as a class could be toxic 
[2]. A more recent publication by the same group (without publicity) 
demonstrated that the originally observed “toxicity” was due to 
impurities in the sample [3]. Even more recently these original studies 
were “formally” debunked by a follow-up publication which stated that 
the original Oberdorster studies where “compromised by experimental 
artifacts” [4]. On the opposite end of the spectrum, studies in mice 
demonstrate that similar C60 preparations significantly increase the 
lifespan of mice [5]. Thus, it is difficult for researchers, and the general 
public, to determine if fullerenes are dangerous nanostructures that 
should be banned or a potential novel platform for developing new 
fountain-of-youth medicines. How can a class of compounds be 
simultaneously toxic and lifespan extenders?
Contributing to the confusion is that few studies examining 
toxicity use well characterized and highly purified material that are 
not mixtures of many isomers, aggregate sizes, and impurities. Most 
studies in which fullerenes are deemed to be toxic use starting material 
with little or no characterization (DLS, zeta potential, FTIR, etc.). In 
addition, no studies have compared differences in cage sizes (C60 vs. 
C70 vs. C80); the latter two are much more likely to become US Food 
and Drug Administration (FDA) approved products due to their size 
being conducive to fewer numbers of isomers when adding side chain 
moieties. The FDA requires that every new chemical entity (NCE) 
must be evaluated separately; extrapolating toxicity (or non-toxicity) 
by categorizing compound mixtures and making generalizations 
about classes of compounds (as is the case with fullerenes) with 
many different isomers is not acceptable to the FDA. Anyone with a 
high school-level understanding of basic chemistry is aware that even 
extremely similar molecules can have different biologic activities. 
There are many examples where two isomers that are very similar have 
completely different biological behavior. For example, the tragedy of 
the drug thalidomide, where one isoform was an effective sedative and 
the mirror image isoform was teratogenic resulting in fetal defects, 
changed the face of drug testing. This applies to the studies with 
fullerenes where even extremely small changes in the core fullerene 
structure (through the addition of side-chain moieties) can result in 
the FD having completely different biological properties. This has been 
demonstrated repeatedly by several laboratories which highlight the 
difficulty in interpreting data gathered from extrapolating findings 
between even very similar compounds. 
Complicating the task of bringing FD to the marketplace is the fact 
that the FDA does not have specific guidelines for products containing 
nanoscale materials. A report issued by the FDA Nanotechnology 
Task Force (July 2007) recommends guidance by various centers 
within the FDA for industries working with nanomaterials. Unlike 
“standard” drug products it is increasingly evident that at least in 
the area of characterization of nanomaterials used in drug products, 
different standards apply. Applying small molecule principles and 
methodologies to nanomaterials cannot be extrapolated in biological 
settings. The study stressed that biodistribution analysis should be at 
the core of any evaluation of products containing nanomaterials. These 
biodistribution studies, as recommended by the FDA, provide valuable 
information on where the nanoparticles are traveling and possibly 
accumulating, therefore subjecting those sites to increased likelihood 
of toxicological effects. It was also stressed in the 2007 report that most 
studies (using nanomaterials) are limited in that they are short-term, 
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Figure 1: Representative fullerene structures.
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and might leave long-term effects unevaluated, especially because the 
long-term toxicity and effects for most nanoscale materials remain 
unknown. Furthermore, appropriate endpoints for in vitro assays 
are seen to be difficult to determine, as single cell types are often not 
sufficient for evaluation on the function or health of organs or tissues 
that are made up of multiple cell types, and given that numerous types 
of tissues are exposed to in the body. The major recommendation was 
that nanoscale material be characterized with respect to size (surface 
area and size distribution), chemical composition (such as purity and 
crystallinity), surface structure (surface reactivity, surface groups, 
coatings, etc.), solubility, shape, and aggregation. The protocols 
developed at the National Cancer Institute’s, Nanotechnology 
Characterization Laboratories was recommended as being very useful 
in helping to characterize nanoscale materials and to develop standards 
and standardized methods for measuring nanoscale materials.
The potential for using fullerene-based medicines is substantial 
but concerns of toxicity have slowed the initial enthusiasm that 
surrounded their discovery. Only those studies using well characterized, 
single species “lead candidate” fullerene formulations can provide 
meaningful information regarding potential toxicological effects. 
Such studies are needed as the state of research today with fullerenes 
is shaped by studies such as these that address the observation “that 
extrapolation across similar nanoparticles will be dependent upon 
surface chemistry and concentration which may affect the degree of 
agglomeration and thus biological effects” [6]. Thus, more thorough 
studies will serve as a building block in developing a database that links 
surface functionalization chemistry of fullerene compounds to biologic 
function.
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